IL304240A - Methods for treating peanut allergy and improving immunotherapy for a specific peanut allergen by administering an il-4r antagonist - Google Patents

Methods for treating peanut allergy and improving immunotherapy for a specific peanut allergen by administering an il-4r antagonist

Info

Publication number
IL304240A
IL304240A IL304240A IL30424023A IL304240A IL 304240 A IL304240 A IL 304240A IL 304240 A IL304240 A IL 304240A IL 30424023 A IL30424023 A IL 30424023A IL 304240 A IL304240 A IL 304240A
Authority
IL
Israel
Prior art keywords
peanut
antagonist
administering
methods
enhancing
Prior art date
Application number
IL304240A
Other languages
English (en)
Hebrew (he)
Inventor
Jamie M Orengo
Allen Radin
Marcella Ruddy
Heribert Staudinger
Qiufan Wang
Original Assignee
Regeneron Pharma
Sanofi Biotechnology
Jamie M Orengo
Allen Radin
Marcella Ruddy
Heribert Staudinger
Qiufan Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Sanofi Biotechnology, Jamie M Orengo, Allen Radin, Marcella Ruddy, Heribert Staudinger, Qiufan Wang filed Critical Regeneron Pharma
Publication of IL304240A publication Critical patent/IL304240A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL304240A 2021-01-08 2023-07-04 Methods for treating peanut allergy and improving immunotherapy for a specific peanut allergen by administering an il-4r antagonist IL304240A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163135238P 2021-01-08 2021-01-08
EP21315241 2021-11-10
PCT/US2022/011643 WO2022150605A1 (en) 2021-01-08 2022-01-07 Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist

Publications (1)

Publication Number Publication Date
IL304240A true IL304240A (en) 2023-09-01

Family

ID=80034850

Family Applications (1)

Application Number Title Priority Date Filing Date
IL304240A IL304240A (en) 2021-01-08 2023-07-04 Methods for treating peanut allergy and improving immunotherapy for a specific peanut allergen by administering an il-4r antagonist

Country Status (9)

Country Link
US (1) US20220220211A1 (cg-RX-API-DMAC7.html)
EP (1) EP4274609A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024502471A (cg-RX-API-DMAC7.html)
KR (1) KR20230130681A (cg-RX-API-DMAC7.html)
AU (1) AU2022206434A1 (cg-RX-API-DMAC7.html)
CA (1) CA3204515A1 (cg-RX-API-DMAC7.html)
IL (1) IL304240A (cg-RX-API-DMAC7.html)
MX (1) MX2023007945A (cg-RX-API-DMAC7.html)
WO (1) WO2022150605A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
CN118286417A (zh) 2012-09-07 2024-07-05 瑞泽恩制药公司 以il-4r拮抗剂治疗特应性皮炎的方法
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法
PT3110848T (pt) 2014-09-24 2024-03-05 Regeneron Pharma Métodos para tratamento de infeção cutânea por administração de um antagonista do il-4r
KR102872485B1 (ko) 2016-09-01 2025-10-20 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법
KR20210143246A (ko) 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
JP7736667B2 (ja) 2019-08-05 2025-09-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Il-4rアンタゴニストを投与することによるアトピー性皮膚炎の治療方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2990420T (pt) 2000-05-26 2017-03-16 Immunex Corp Uso de anticorpos de recetor de interleucina-4 e composições dos mesmos
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
UA93653C2 (ru) 2003-11-07 2011-03-10 Иммунекс Корпорейшн Выделенное антитело, kotopoe специфически связывается c человеческим рецептором il-4 (il-4r)
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
CA2664343C (en) 2006-10-02 2016-04-26 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
MX366337B (es) 2010-10-06 2019-07-05 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r).
WO2014159609A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Peanut formulations and uses thereof
MX2015010315A (es) 2013-03-14 2016-04-13 Aimmune Therapeutics Inc Fabricacion de formulaciones de mani para desensibilizacion oral.
TWI755763B (zh) * 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
CN107474134B (zh) 2016-06-08 2021-07-27 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
KR102872485B1 (ko) * 2016-09-01 2025-10-20 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법
EP4406975A3 (en) * 2018-06-14 2024-11-13 Ajinomoto Co., Inc. Compound having affinity substance to antibody and bioorthogonal functional group, or salt thereof
KR102330596B1 (ko) 2018-11-09 2021-11-26 아주대학교산학협력단 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도
KR20210143246A (ko) * 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
US11504426B2 (en) * 2019-08-05 2022-11-22 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist

Also Published As

Publication number Publication date
JP2024502471A (ja) 2024-01-19
KR20230130681A (ko) 2023-09-12
US20220220211A1 (en) 2022-07-14
CA3204515A1 (en) 2022-07-14
EP4274609A1 (en) 2023-11-15
AU2022206434A1 (en) 2023-08-24
MX2023007945A (es) 2023-09-21
WO2022150605A1 (en) 2022-07-14

Similar Documents

Publication Publication Date Title
SG11202113312VA (en) Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist
IL273678A (en) Methods for treating allergy and improving allergen-specific immunotherapy by administering an il-4r inhibitor
MX2023007945A (es) Metodos para tratar la alergia al cacahuate y mejorar la inmunoterapia especifica de alergeno del cacahuate mediante la administracion de un antagonista de il-4r.
IL278812A (en) Peptides and methods for detecting peanut allergies
PL3770547T3 (pl) Urządzenie do analizy bloków i sposób oceny bloków
EP3333733A4 (en) Method and device for use in parallel execution of terminal database
DK2144555T4 (da) Indretning og fremgangsmåde til transkutan bestemmelse af blodgasser
RS67826B1 (sr) Postupak za lečenje alergije sa monoklonskim antitelima specifičnim za alergen
MY184189A (en) Methods of treating nail and scalp psoriasis
GB2619178B (en) Analysis device and analysis method
SG11202102591TA (en) Fpga-based resequencing analysis method and device
IL289731A (en) Methods for treating or preventing asthma by administering an antagonist to il-4r
PL3472610T3 (pl) Zwarte urządzenie do analizy gazu i sposób
IL312187A (en) Methods for treating prurigo nodularis by administering an IL-4R antagonist
GB2584597B (en) Security device and method of manufacture thereof
GB2494780B (en) Apparatus and method of concentric cement bonding operations before and after cementation
HK40096432A (en) Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
EP3943124A4 (en) GAS TREATMENT SYSTEM AND METHOD
IL292238A (en) Sequences of clec12a antibody fragments and methods
HK40067333A (en) Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist
GB2603060B (en) Unit verification method and device
GB201912817D0 (en) Settlement analyser and method of analysing settlement
ES2530440A1 (es) Metodo para el pronostico de la eficacia de la inmunoterapia oral para el tratamiento de la alergia a las proteinas de leche de vaca
IL287766A (en) Gas treatment method and gas treatment device
GB201801983D0 (en) An exhaust gas treatment device and method